Pasar al contenido principal

BIOENERGETICA Y METABOLISMO EN LA ENFERMEDAD DE PARKINSON

PID2022-136685OA-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE SEVILLA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Phosphodiesterase Inhibition Increases Striatal GDNF and Protects Against Preclinical Parkinsonism

  • d’Anglemont de Tassigny, Xavier
  • Jiménez-Medina, Alejandro
  • López-López, Ivette
  • López-Barneo, José
Glial cell line-derived neurotrophic factor (GDNF) has been investigated as a therapeutic agent for Parkinson's disease (PD), albeit with variable clinical outcomes. In the brain, GDNF is predominantly produced by striatal interneurons. Given that Gdnf gene expression is regulated by cyclic adenosine monophosphate (cAMP)-dependent signaling, a compelling strategy for PD treatment is the pharmacological elevation of intracellular cAMP. This approach aims to enhance endogenous GDNF, offering potential neuroprotective benefits. In this study, we show that selective inhibition of phosphodiesterases (PDEs) subtypes, therefore enhancing intracellular cAMP levels, increases Gdnf mRNA expression in striatal slices ex vivo; however, achieving this effect in vivo proved more challenging. To address this, we evaluated Ibudilast, a clinically approved non-selective PDE inhibitor. Ibudilast robustly upregulated striatal Gdnf expression both ex vivo and in vivo following systemic administration. In a chronic MPTP mouse model of PD, Ibudilast treatment conferred significant neuroprotection, as evidenced by preservation of tyrosine hydroxylase-positive (TH+) neurons in the substantia nigra, attenuation of TH+ fiber loss in the striatum, and mitigation of striatal dopamine depletion. Given its established clinical use and favorable safety profile, these findings support further investigation of Ibudilast as a potential disease-modifying therapy in PD., This study was supported by Fundación Tatiana Pérez de Guzmán el Bueno Foundation, Spanish Ministry of Science, Innovation and Universities (PID2022-138131OB-I00, PREP2022-000587), and Andalusian Plan for Research, Development and Innovation (P18-RT-3100)., We appreciate support from the “Tatiana Pérez de Guzman el Bueno Foundation,” the Andalusian Plan for Research, Development and Innovation (PAIDI2020, project P18-RT-3100), and the Spanish Ministry of Science, Innovation and Universities (projects PID2022-138131OB-I00, PREP2022-000587, and PID2022-136685OA-I00). We are grateful to the mass spectrometry core facility (Citius) and Dr. Martiniano Santiago Pavon (Dept. of Pharmacy, University of Seville) for consultation and special reagent supply., Peer reviewed